|
Home : Unsafe Drugs : Avandia : Newsfeeds : Glaxo Posts First-Quarter EPS of 32.2 Pence, Surpassing Analyst Estimates Glaxo Posts First-Quarter EPS of 32.2 Pence, Surpassing Analyst Estimates
Revenue from the Avandia diabetes medicine plunged after the company stopped promoting it worldwide because of an increased risk of heart attacks. “The first quarter was probably the toughest for Glaxo in terms of year-on-year comparisons for generic ...
Avandia Case Evaluation Form
This form is secure and encrypted. More information about secure forms and your privacy here.
|




